Which has stronger valuation and earnings, LRMR or RNTX?

Larimar Therapeutics is trading at a lower price-to-earnings ratio than Rein Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Larimar Therapeutics N/A N/A -$165.67M -$2.06 N/A Rein Therapeutics N/A N/A -$49.87M -$1.90 N/A

Is LRMR or RNTX more profitable?

Rein Therapeutics' return on equity of 0.00% beat Larimar Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Larimar Therapeutics N/A -134.14% -96.00% Rein Therapeutics N/A N/A -68.14%

Does the media prefer LRMR or RNTX?

In the previous week, Larimar Therapeutics had 8 more articles in the media than Rein Therapeutics. MarketBeat recorded 12 mentions for Larimar Therapeutics and 4 mentions for Rein Therapeutics. Larimar Therapeutics' average media sentiment score of 1.07 beat Rein Therapeutics' score of 0.54 indicating that Larimar Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Larimar Therapeutics 3 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Rein Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings and valuation, IMRX or RNTX?

Immuneering is trading at a lower price-to-earnings ratio than Rein Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Immuneering N/A N/A -$56.03M -$1.17 N/A Rein Therapeutics N/A N/A -$49.87M -$1.90 N/A

Is IMRX or RNTX more profitable?

Rein Therapeutics' return on equity of 0.00% beat Immuneering's return on equity. Company Net Margins Return on Equity Return on Assets Immuneering N/A -31.93% -29.92% Rein Therapeutics N/A N/A -68.14%

Does the media favor IMRX or RNTX?

In the previous week, Immuneering had 2 more articles in the media than Rein Therapeutics. MarketBeat recorded 6 mentions for Immuneering and 4 mentions for Rein Therapeutics. Immuneering's average media sentiment score of 0.93 beat Rein Therapeutics' score of 0.54 indicating that Immuneering is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Immuneering 0 Very Positive mention(s) 4 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Rein Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor AKBA or RNTX?

In the previous week, Akebia Therapeutics and Akebia Therapeutics both had 4 articles in the media. Akebia Therapeutics' average media sentiment score of 1.55 beat Rein Therapeutics' score of 0.54 indicating that Akebia Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Akebia Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Rein Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate NLTX or RNTX?

Rein Therapeutics has a consensus price target of $7.00, indicating a potential upside of 671.35%. Given Rein Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Rein Therapeutics is more favorable than Neoleukin Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Neoleukin Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Rein Therapeutics 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has better earnings and valuation, NLTX or RNTX?

Neoleukin Therapeutics is trading at a lower price-to-earnings ratio than Rein Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Neoleukin Therapeutics N/A N/A -$57.56M -$3.11 N/A Rein Therapeutics N/A N/A -$49.87M -$1.90 N/A

Is NLTX or RNTX more profitable?

Rein Therapeutics' return on equity of 0.00% beat Neoleukin Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Neoleukin Therapeutics N/A -37.22% -30.91% Rein Therapeutics N/A N/A -68.14%

Rein Therapeutics (RNTX) Competitors

$0.91 -0.07 (-7.40%)

Closing price 07/13/2026 04:00 PM Eastern

Extended Trading

$0.90 0.00 (-0.39%)

As of 07/13/2026 07:51 PM Eastern

Compare

RNTX vs. LRMR, IMRX, AKBA, NLTX, and CLLS

Should you buy Rein Therapeutics stock or one of its competitors? MarketBeat compares Rein Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Rein Therapeutics include Larimar Therapeutics (LRMR), Immuneering (IMRX), Akebia Therapeutics (AKBA), Neoleukin Therapeutics (NLTX), and Cellectis (CLLS). These companies are all part of the "pharmaceutical products" industry.

How does Rein Therapeutics compare to Larimar Therapeutics?

Larimar Therapeutics (NASDAQ:LRMR) and Rein Therapeutics (NASDAQ:RNTX) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, media sentiment, dividends, risk, analyst recommendations, institutional ownership, valuation and earnings.

In the previous week, Larimar Therapeutics had 8 more articles in the media than Rein Therapeutics. MarketBeat recorded 12 mentions for Larimar Therapeutics and 4 mentions for Rein Therapeutics. Larimar Therapeutics' average media sentiment score of 1.07 beat Rein Therapeutics' score of 0.54 indicating that Larimar Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Larimar Therapeutics	3 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Rein Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

91.9% of Larimar Therapeutics shares are held by institutional investors. Comparatively, 90.9% of Rein Therapeutics shares are held by institutional investors. 4.5% of Larimar Therapeutics shares are held by insiders. Comparatively, 1.5% of Rein Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Larimar Therapeutics currently has a consensus target price of $12.71, suggesting a potential upside of 241.78%. Rein Therapeutics has a consensus target price of $7.00, suggesting a potential upside of 671.35%. Given Rein Therapeutics' higher possible upside, analysts plainly believe Rein Therapeutics is more favorable than Larimar Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Larimar Therapeutics	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	3 Strong Buy rating(s)	3.09
Rein Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Larimar Therapeutics has a beta of 0.83, suggesting that its stock price is 17% less volatile than the broader market. Comparatively, Rein Therapeutics has a beta of 1.35, suggesting that its stock price is 35% more volatile than the broader market.

Larimar Therapeutics is trading at a lower price-to-earnings ratio than Rein Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Larimar Therapeutics	N/A	N/A	-$165.67M	-$2.06	N/A
Rein Therapeutics	N/A	N/A	-$49.87M	-$1.90	N/A

Rein Therapeutics' return on equity of 0.00% beat Larimar Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Larimar Therapeutics	N/A	-134.14%	-96.00%
Rein Therapeutics	N/A	N/A	-68.14%

Summary

Larimar Therapeutics and Rein Therapeutics tied by winning 7 of the 14 factors compared between the two stocks.

How does Rein Therapeutics compare to Immuneering?

Immuneering (NASDAQ:IMRX) and Rein Therapeutics (NASDAQ:RNTX) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, institutional ownership, dividends, valuation, media sentiment, analyst recommendations, earnings and risk.

Immuneering currently has a consensus target price of $16.57, indicating a potential upside of 221.15%. Rein Therapeutics has a consensus target price of $7.00, indicating a potential upside of 671.35%. Given Rein Therapeutics' higher possible upside, analysts clearly believe Rein Therapeutics is more favorable than Immuneering.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immuneering	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86
Rein Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Immuneering had 2 more articles in the media than Rein Therapeutics. MarketBeat recorded 6 mentions for Immuneering and 4 mentions for Rein Therapeutics. Immuneering's average media sentiment score of 0.93 beat Rein Therapeutics' score of 0.54 indicating that Immuneering is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immuneering	0 Very Positive mention(s)	4 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Rein Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Immuneering has a beta of 0.41, meaning that its stock price is 59% less volatile than the broader market. Comparatively, Rein Therapeutics has a beta of 1.35, meaning that its stock price is 35% more volatile than the broader market.

67.7% of Immuneering shares are owned by institutional investors. Comparatively, 90.9% of Rein Therapeutics shares are owned by institutional investors. 22.9% of Immuneering shares are owned by company insiders. Comparatively, 1.5% of Rein Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Rein Therapeutics' return on equity of 0.00% beat Immuneering's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immuneering	N/A	-31.93%	-29.92%
Rein Therapeutics	N/A	N/A	-68.14%

Immuneering is trading at a lower price-to-earnings ratio than Rein Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immuneering	N/A	N/A	-$56.03M	-$1.17	N/A
Rein Therapeutics	N/A	N/A	-$49.87M	-$1.90	N/A

Summary

Immuneering beats Rein Therapeutics on 8 of the 14 factors compared between the two stocks.

How does Rein Therapeutics compare to Akebia Therapeutics?

Akebia Therapeutics (NASDAQ:AKBA) and Rein Therapeutics (NASDAQ:RNTX) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, risk, earnings, institutional ownership, profitability, analyst recommendations, dividends and media sentiment.

33.9% of Akebia Therapeutics shares are owned by institutional investors. Comparatively, 90.9% of Rein Therapeutics shares are owned by institutional investors. 4.3% of Akebia Therapeutics shares are owned by company insiders. Comparatively, 1.5% of Rein Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

In the previous week, Akebia Therapeutics and Akebia Therapeutics both had 4 articles in the media. Akebia Therapeutics' average media sentiment score of 1.55 beat Rein Therapeutics' score of 0.54 indicating that Akebia Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Akebia Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Rein Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Akebia Therapeutics has a beta of 0.23, indicating that its share price is 77% less volatile than the broader market. Comparatively, Rein Therapeutics has a beta of 1.35, indicating that its share price is 35% more volatile than the broader market.

Rein Therapeutics has a net margin of 0.00% compared to Akebia Therapeutics' net margin of -8.83%. Rein Therapeutics' return on equity of 0.00% beat Akebia Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Akebia Therapeutics	-8.83%	-62.72%	-5.66%
Rein Therapeutics	N/A	N/A	-68.14%

Akebia Therapeutics currently has a consensus price target of $4.67, indicating a potential upside of 238.16%. Rein Therapeutics has a consensus price target of $7.00, indicating a potential upside of 671.35%. Given Rein Therapeutics' higher possible upside, analysts clearly believe Rein Therapeutics is more favorable than Akebia Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Akebia Therapeutics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Rein Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Akebia Therapeutics has higher revenue and earnings than Rein Therapeutics. Akebia Therapeutics is trading at a lower price-to-earnings ratio than Rein Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Akebia Therapeutics	$236.20M	1.57	-$5.34M	-$0.08	N/A
Rein Therapeutics	N/A	N/A	-$49.87M	-$1.90	N/A

Summary

Akebia Therapeutics beats Rein Therapeutics on 8 of the 14 factors compared between the two stocks.

How does Rein Therapeutics compare to Neoleukin Therapeutics?

Neoleukin Therapeutics (NASDAQ:NLTX) and Rein Therapeutics (NASDAQ:RNTX) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, profitability, earnings, institutional ownership, analyst recommendations, valuation, dividends and media sentiment.

Neoleukin Therapeutics has a beta of 1.11, suggesting that its stock price is 11% more volatile than the broader market. Comparatively, Rein Therapeutics has a beta of 1.35, suggesting that its stock price is 35% more volatile than the broader market.

Neoleukin Therapeutics is trading at a lower price-to-earnings ratio than Rein Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Neoleukin Therapeutics	N/A	N/A	-$57.56M	-$3.11	N/A
Rein Therapeutics	N/A	N/A	-$49.87M	-$1.90	N/A

In the previous week, Rein Therapeutics had 4 more articles in the media than Neoleukin Therapeutics. MarketBeat recorded 4 mentions for Rein Therapeutics and 0 mentions for Neoleukin Therapeutics. Rein Therapeutics' average media sentiment score of 0.54 beat Neoleukin Therapeutics' score of 0.00 indicating that Rein Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Neoleukin Therapeutics	Neutral
Rein Therapeutics	Positive

Rein Therapeutics has a consensus price target of $7.00, indicating a potential upside of 671.35%. Given Rein Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Rein Therapeutics is more favorable than Neoleukin Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Neoleukin Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Rein Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

52.4% of Neoleukin Therapeutics shares are owned by institutional investors. Comparatively, 90.9% of Rein Therapeutics shares are owned by institutional investors. 1.6% of Neoleukin Therapeutics shares are owned by company insiders. Comparatively, 1.5% of Rein Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Rein Therapeutics' return on equity of 0.00% beat Neoleukin Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Neoleukin Therapeutics	N/A	-37.22%	-30.91%
Rein Therapeutics	N/A	N/A	-68.14%

Summary

Rein Therapeutics beats Neoleukin Therapeutics on 11 of the 13 factors compared between the two stocks.

How does Rein Therapeutics compare to Cellectis?

Cellectis (NASDAQ:CLLS) and Rein Therapeutics (NASDAQ:RNTX) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, profitability, earnings, dividends, institutional ownership, media sentiment, analyst recommendations and valuation.

Rein Therapeutics has a net margin of 0.00% compared to Cellectis' net margin of -89.51%. Rein Therapeutics' return on equity of 0.00% beat Cellectis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cellectis	-89.51%	-80.66%	-20.51%
Rein Therapeutics	N/A	N/A	-68.14%

63.9% of Cellectis shares are owned by institutional investors. Comparatively, 90.9% of Rein Therapeutics shares are owned by institutional investors. 16.4% of Cellectis shares are owned by insiders. Comparatively, 1.5% of Rein Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Cellectis has a beta of 2.88, suggesting that its stock price is 188% more volatile than the broader market. Comparatively, Rein Therapeutics has a beta of 1.35, suggesting that its stock price is 35% more volatile than the broader market.

Cellectis currently has a consensus target price of $7.00, indicating a potential upside of 141.38%. Rein Therapeutics has a consensus target price of $7.00, indicating a potential upside of 671.35%. Given Rein Therapeutics' higher probable upside, analysts clearly believe Rein Therapeutics is more favorable than Cellectis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cellectis	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83
Rein Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Rein Therapeutics has lower revenue, but higher earnings than Cellectis. Cellectis is trading at a lower price-to-earnings ratio than Rein Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cellectis	$79.59M	3.66	-$67.59M	-$0.67	N/A
Rein Therapeutics	N/A	N/A	-$49.87M	-$1.90	N/A

In the previous week, Rein Therapeutics had 3 more articles in the media than Cellectis. MarketBeat recorded 4 mentions for Rein Therapeutics and 1 mentions for Cellectis. Cellectis' average media sentiment score of 1.87 beat Rein Therapeutics' score of 0.54 indicating that Cellectis is being referred to more favorably in the media.

Company	Overall Sentiment
Cellectis	Very Positive
Rein Therapeutics	Positive

Summary

Cellectis beats Rein Therapeutics on 9 of the 16 factors compared between the two stocks.

Get Rein Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RNTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

RNTX vs. The Competition

Export

Metric	Rein Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$83.83M	$3.71B	$7.05B	$12.61B
Dividend Yield	N/A	2.20%	2.68%	8.00%
P/E Ratio	-0.48	20.85	27.11	24.26
Price / Sales	N/A	314.01	587.92	117.88
Price / Cash	17.14	61.98	29.22	49.36
Price / Book	-0.85	8.49	10.75	6.29
Net Income	-$49.87M	$23.83M	$3.58B	$330.66M
7 Day Performance	-10.15%	-3.56%	-2.06%	-1.32%
1 Month Performance	-5.26%	6.31%	3.32%	-0.64%
1 Year Performance	-39.50%	48.30%	26.35%	19.08%

Rein Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
RNTX Rein Therapeutics	3.5177 of 5 stars	$0.91 -7.4%	$7.00 +671.3%	-37.0%	$83.83M	N/A	N/A	9	News Coverage Short Interest Increase Gap Down
LRMR Larimar Therapeutics	4.3519 of 5 stars	$3.26 flat	$12.71 +290.0%	+10.1%	$338.65M	N/A	N/A	30	Positive News Gap Down
IMRX Immuneering	3.1098 of 5 stars	$5.19 flat	$16.50 +217.9%	+16.7%	$335.79M	N/A	N/A	60	News Coverage Analyst Upgrade
AKBA Akebia Therapeutics	3.2543 of 5 stars	$1.24 flat	$4.67 +276.3%	-64.9%	$332.64M	$236.20M	N/A	430	Short Interest Decrease
NLTX Neoleukin Therapeutics	N/A	$35.34 +4.3%	N/A	+84.9%	$332.13M	N/A	N/A	90	High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:RNTX) was last updated on 7/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rein Therapeutics (RNTX) Competitors

RNTX vs. LRMR, IMRX, AKBA, NLTX, and CLLS

How does Rein Therapeutics compare to Larimar Therapeutics?

Summary

How does Rein Therapeutics compare to Immuneering?

Summary

How does Rein Therapeutics compare to Akebia Therapeutics?

Summary

How does Rein Therapeutics compare to Neoleukin Therapeutics?

Summary

How does Rein Therapeutics compare to Cellectis?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RNTX vs. The Competition

Rein Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Rein Therapeutics (RNTX) Competitors

RNTX vs. LRMR, IMRX, AKBA, NLTX, and CLLS

How does Rein Therapeutics compare to Larimar Therapeutics?

Does the media prefer LRMR or RNTX?

Do institutionals and insiders hold more shares of LRMR or RNTX?

Do analysts rate LRMR or RNTX?

Which has more volatility & risk, LRMR or RNTX?

Which has stronger valuation and earnings, LRMR or RNTX?

Is LRMR or RNTX more profitable?

Summary

How does Rein Therapeutics compare to Immuneering?

Do analysts rate IMRX or RNTX?

Does the media favor IMRX or RNTX?

Which has more risk & volatility, IMRX or RNTX?

Do insiders & institutionals believe in IMRX or RNTX?

Is IMRX or RNTX more profitable?

Which has stronger earnings and valuation, IMRX or RNTX?

Summary

How does Rein Therapeutics compare to Akebia Therapeutics?

Do institutionals and insiders believe in AKBA or RNTX?

Does the media favor AKBA or RNTX?

Which has more risk and volatility, AKBA or RNTX?

Is AKBA or RNTX more profitable?

Do analysts prefer AKBA or RNTX?

Which has higher valuation and earnings, AKBA or RNTX?

Summary

How does Rein Therapeutics compare to Neoleukin Therapeutics?

Which has more volatility & risk, NLTX or RNTX?

Which has better earnings and valuation, NLTX or RNTX?

Does the media refer more to NLTX or RNTX?

Do analysts rate NLTX or RNTX?

Do insiders & institutionals believe in NLTX or RNTX?

Is NLTX or RNTX more profitable?

Summary

How does Rein Therapeutics compare to Cellectis?

Is CLLS or RNTX more profitable?

Do institutionals and insiders believe in CLLS or RNTX?

Which has more risk and volatility, CLLS or RNTX?

Do analysts rate CLLS or RNTX?

Which has higher valuation and earnings, CLLS or RNTX?

Does the media refer more to CLLS or RNTX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RNTX vs. The Competition

Rein Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools